Hypotension
Drug research and approvals for hypotension: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 164 studies of hypotension are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, FDA has 2 approved and 2 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 164
- Trials authorized in Canada: 9
- FDA orphan approvals: 2
- EU medicines: 2
- Diagnostic Accuracy of Combined Perfusion Index, Internal Jugular Vein Collapsibility Index and Cardiac Index in…NCT07947550 · Not reported · Menoufia University · starts Dec 1, 2026
- Postprandial Hypotension, Frailty and Post-Induction Hypotension in Older Patients Undergoing Noncardiac SurgeryNCT07914920 · Not reported · Konya City Hospital · starts Nov 5, 2026
- Cardiac Arrest - Ultrasound Detection of Occult PerfusionNCT07897370 · Not reported · University of Massachusetts, Worcester · starts Oct 1, 2026
- Granisetron Use, Blood Pressure, and Nausea and Vomiting During Cesarean Delivery Under Spinal AnesthesiaNCT07861737 · Not reported · Kayseri City Hospital · starts Oct 15, 2026
- Modified Saddle Block vs Spinal Anesthesia for TURPNCT07841184 · Phase 4 · Pakistan Institute of Medical Sciences · starts Aug 25, 2026
- The Relationship Between Hypotension and Tissue O2 in Invasive Eadyn During Anesthesia Induction in Open Heart SurgeryNCT07831252 · Not reported · Haseki Training and Research Hospital · starts Sep 1, 2025
- Effects of Different MAP Targets on Ocular Perfusion and Optic Nerve Microvasculature During RhinoplastyNCT07832305 · Not applicable · Hitit University · starts Sep 20, 2026
- Effect of Remimazolam Versus Propofol Total Intravenous Anesthesia on Intraoperative Hemodynamic Stability in Patients…NCT07806006 · Phase 4 · Seoul National University Hospital · starts Oct 1, 2026
- Preoperative Neutrophil-to-Albumin Ratio and Post-Induction Hemodynamic Vulnerability in Major Oncologic SurgeryNCT07804706 · Not reported · Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · starts Sep 1, 2026
Approved 5
- PhenylephrineAdrenergic receptor alpha-1 agonist
- NorepinephrineAdrenergic receptor agonist
- EphedrineAdrenergic receptor agonist
- DopamineBeta-1 adrenergic receptor agonist
- Angiotensin iiType-1 angiotensin II receptor agonist
Phase 3 6
- OndansetronSerotonin 3a (5-HT3a) receptor antagonist
- MidodrineAdrenergic receptor alpha-1 agonist
- Drotrecogin alfa (activated)Coagulation factor VIII inhibitor
- IcatibantBradykinin B2 receptor antagonist
- RopivacaineSodium channel alpha subunit blocker
- Levocarnitine
Phase 2 12 of 16
- BupivacaineSodium channel protein type IV alpha subunit blocker
- FentanylMu opioid receptor agonist
- MeperidineMu opioid receptor agonist
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- PropranololBeta-1 adrenergic receptor antagonist
- PyridostigmineAcetylcholinesterase inhibitor
- NitroprussideSoluble guanylate cyclase activator
- DroxidopaAdrenergic receptor agonist
- MetaraminolAdrenergic receptor alpha-1 agonist
- PropofolGABA-A receptor; anion channel positive allosteric modulator
- EpinephrineAdrenergic receptor agonist
- Fospropofol
Phase 1 or earlier 8
- DexmedetomidineAdrenergic receptor alpha-2 agonist
- Imisopasem manganeseSOD mimic (antioxidant)
- NitroglycerinSoluble guanylate cyclase activator
- Hydroxyethyl starch 130/0.4
- Tranexamic acidPlasminogen inhibitor
- DiltiazemVoltage-gated L-type calcium channel blocker
- LabetalolAdrenergic receptor antagonist
- VasopressinVasopressin receptor agonist
How its trials ended
994 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 163 whose ending is known, 46% met their primary endpoint, 9% missed it and 45% stopped early.
- Completed, result not reported47348%
- Ongoing20521%
- Status unknown15315%
- Met its primary endpoint758%
- Stopped: other or unclear495%
- Stopped: enrollment or feasibility162%
- Missed its primary endpoint152%
- Stopped: funding4<1%
- Stopped: sponsor or business decision3<1%
- Stopped: safety1<1%
| Mar 26, 2026 | Controlled CO2 inhalation to increase blood pressure in neurogenic orthostatic hypotension: a proof-of-concept novel therapy studyCarbon dioxide | Governors of The University of Calgary | Ongoing |
| Jan 27, 2020 | A phase 3, 182-week, open-label, safety and tolerability study of TD-9855 in treating symptomatic neurogenic orthostatic hypotension (SNOH) in subjects with…Ampreloxetine (TD-9855) | Theravance Biopharma | Closed |
| Jun 24, 2019 | A phase 3, 22-week, multi-center, randomized withdrawal study of td¿9855 in treating symptomatic neurogenic orthostatic hypotension in subjects with primary…Ampreloxetine (TD-9855) | Theravance Biopharma | Closed |
| Feb 28, 2019 | A phase 3, 4-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of TD-9855 in treating symptomatic neurogenic orthostatic…Ampreloxetine (TD-9855) | Theravance Biopharma | Closed |
| Jan 20, 2016 | Norepinephrine to prevent hypotension after spinal anesthesia for cesarean delivery: a dose finding studyNorepinephrine | Mount Sinai Hospital | Pending |
| Nov 10, 2015 | A phase 3, placebo-controlled, randomized, double-blind, multi- center study of LJPC-501 in patients with catecholamine-resistant hypotension (CRH)LJPC-501 | La Jolla Pharmaceutical | Ongoing |
| May 29, 2015 | Management of hypotension in the preterm: a multi centre, randomised, controlled trial of hypotension management in the extremely low gestational age new-bornDopamine | Brepco Biopharma Limited | Closed |
| Dec 11, 2013 | Phoenix: a clinical study of patients with symptomatic neurogenic orthostatic hypotension to assess sustained effects of droxidopa therapyDroxidopa | Chelsea Therapeutics | Ongoing |
| Nov 5, 2013 | Acarbose and older adults with postprandial hypotensionAcarbose | Dr Kenneth Madden | Ongoing |
| Feb 18, 2014 | NortheraTreatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic… | Lundbeck LLC | Approved |
| Sep 6, 1996 | AmatineTreatment of symptomatic orthostatic hypotension. | Takeda Development Center Americas, Inc. | Approved |
| May 9, 2023 | AmpreloxetineTreatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy | Theravance Biopharma Ireland Limited | Designated |
| Aug 29, 2016 | S-ethylisothiourea diethylphosphateTreatment of symptomatic intradialytic hypotension, including symptomatic hypotension in the immediate post-dialytic period. | TrioxBio, Inc. | Designated |
| May 27, 2024 | NeoatriconDopamine hydrochloride | BrePco Biopharma Limited | EMA ↗ |
| Aug 23, 2019 | GiaprezaAngiotensin II | Paion Pharma GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA